Anna Aleskog
Overview
Explore the profile of Anna Aleskog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norberg M, Lindhagen E, Kanduri M, Rickardson L, Sundstrom C, Stamatopoulos K, et al.
Anticancer Res
. 2012 Jul;
32(8):3125-36.
PMID: 22843883
Background/aim: For chronic lymphocytic leukemia (CLL) patients with poor-prognostic genomic aberrations the therapeutic options are limited. We used the Spectrum Collection library to identify compounds with anti-leukemia activity in high-risk...
2.
Haglund C, Aleskog A, Nygren P, Gullbo J, Hoglund M, Wickstrom M, et al.
Cancer Chemother Pharmacol
. 2011 Oct;
69(3):697-707.
PMID: 21984220
Purpose: The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity...
3.
Eriksson A, Hoglund M, Lindhagen E, Aleskog A, Bashir Hassan S, Ekholm C, et al.
Biochem Pharmacol
. 2010 Aug;
80(10):1507-16.
PMID: 20705060
Aberrant signal transduction by mutant or overexpressed protein kinases has emerged as a promising target for treatment of acute myeloid leukemia (AML). We here present a novel low molecular weight...
4.
Haglund C, Aleskog A, Douhan Hakansson L, Hoglund M, Jacobsson S, Larsson R, et al.
Toxicol Lett
. 2010 Feb;
194(3):102-7.
PMID: 20167269
One of the most common dose limiting adverse effects in cancer treatment is myelotoxicity. The aim of this study was to develop an in vitro method for measuring potential myelotoxic...
5.
Mansouri M, Sevov M, Aleskog A, Jondal M, Merup M, Sundstrom C, et al.
Eur J Haematol
. 2009 Nov;
84(2):109-16.
PMID: 19889012
T-cell leukemia/lymphoma protein 1 (TCL1) was recently shown to display an expression pattern in chronic lymphocytic leukemia (CLL) corresponding to molecular subtypes, where poor-risk patients demonstrated higher expression levels. Here,...
6.
Kaderi M, Mansouri M, Zainuddin N, Cahill N, Gunnarsson R, Jansson M, et al.
Leuk Res
. 2009 Jul;
34(3):335-9.
PMID: 19573916
The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this...
7.
Lindhagen E, Norberg M, Kanduri M, Tobin G, Saisanen L, Aberg M, et al.
Eur J Haematol
. 2009 Feb;
83(1):22-34.
PMID: 19245531
Background: There is a need for development of new drugs for treatment of B-cell chronic lymphocytic leukemia (CLL), especially for poor-prognostic subgroups resistant to conventional therapy. Objective: The in vitro...
8.
Aleskog A, Norberg M, Nygren P, Rickardson L, Kanduri M, Tobin G, et al.
Leuk Lymphoma
. 2008 Dec;
49(12):2333-43.
PMID: 19052982
The mammalian target of rapamycin inhibitor rapamycin and its analogues show promising anticancer activity in various experimental tumor models and are presently evaluated in clinical trials. We, here, evaluated the...
9.
Wiberg K, Carlson K, Aleskog A, Larsson R, Nygren P, Lindhagen E
Med Oncol
. 2008 Nov;
26(2):193-201.
PMID: 19016012
Bortezomib represents a new class of anti-cancer drugs, the proteasome inhibitors. We evaluated the in vitro activity of bortezomib with regard to tumour-type specificity and possible mechanisms of drug resistance...
10.
Lindhagen E, Eriksson A, Wickstrom M, Danielsson K, Grundmark B, Henriksson R, et al.
Eur J Haematol
. 2008 Jul;
81(5):344-53.
PMID: 18637032
Objectives: Gefitinib inhibits epidermal growth factor receptor (EGFR) signalling, but may also act by non-EGFR dependent mechanisms. We have investigated the activity of gefitinib in haematological tumour cells, in particular...